{"DataElement":{"publicId":"2427387","version":"1","preferredName":"Prostate Tumor Histopathologic Grade Stage","preferredDefinition":"A system for classifying cancer cells in terms of how abnormal they appear when examined under a microscope which provides information about the probable growth rate in the prostate cancer.  AJCC Cancer Staging Manual, 6th Edition.","longName":"PROS_TUMOR_HISTO_G_S","context":"CTEP","contextVersion":"2.31","DataElementConcept":{"publicId":"2427329","version":"1","preferredName":"Prostate Tumor Histopathologic Grade","preferredDefinition":"A system for classifying cancer cells in terms of how abnormal they appear when examined under a microscope which provides information about the probable growth rate in the prostate cancer.","longName":"PRS_TUMOR_HISTOPAT_G","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2206573","version":"1","preferredName":"Prostate Neoplasm","preferredDefinition":"A gland in the male reproductive system just below the bladder. It surrounds part of the urethra, the canal that empties the bladder. It produces a fluid that forms part of semen. (NCI-GLOSS):(NEE-o-PLAY-zha) Abnormal and uncontrolled cell growth.","longName":"C12410:C3262","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prostate Gland","conceptCode":"C12410","definition":"The walnut shaped accessory sex gland of the male reproductive system. It is located in the pelvis just below the bladder, surrounding the prostatic part of the urethra. The prostate gland secretes a fluid which is part of the semen.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Neoplasm","conceptCode":"C3262","definition":"A benign or malignant tissue growth resulting from uncontrolled cell proliferation. Benign neoplastic cells resemble normal cells without exhibiting significant cytologic atypia, while malignant cells exhibit overt signs such as dysplastic features, atypical mitotic figures, necrosis, nuclear pleomorphism, and anaplasia. Representative examples of benign neoplasms include papillomas, cystadenomas, and lipomas; malignant neoplasms include carcinomas, sarcomas, lymphomas, and leukemias.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F37D0428-FA7A-6787-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-03-29","endDate":null,"createdBy":"SBR","dateCreated":"2005-03-29","modifiedBy":"ONEDATA","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2427327","version":"1","preferredName":"Grade","preferredDefinition":"Describes how closely a cancer resembles normal tissue of its same type, and the cancer's probable rate of growth","longName":"C18000","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Histologic Grade","conceptCode":"C18000","definition":"The degree of abnormality of cancer cells, a measure of differentiation, the extent to which cancer cells are similar in appearance and function to healthy cells of the same tissue type. The degree of differentiation often relates to the clinical behavior of the particular tumor. Based on the microscopic findings, tumor grade is commonly described by one of four degrees of severity. Histopathologic grade of a tumor may be used to plan treatment and estimate the future course, outcome, and overall prognosis of disease. Certain types of cancers, such as soft tissue sarcoma, primary brain tumors, lymphomas, and breast have special grading systems.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"05116195-EBA8-7341-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-09","endDate":null,"createdBy":"ALAIS","dateCreated":"2005-11-09","modifiedBy":"ONEDATA","dateModified":"2005-11-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"AJCC:American Joint Committee on Cancer Cancer Staging Manual, 6th Ed., 2002","workflowStatus":"RELEASED","registrationStatus":"Application","id":"03E16831-BC6E-6D9B-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-09","endDate":null,"createdBy":"ALAIS","dateCreated":"2005-11-09","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":"Updated to AJCC Cancer Staging Manual, 6th Ed","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2427354","version":"1","preferredName":"Prostate Tumor Histopathologic Grade Stage","preferredDefinition":"A system for classifying cancer cells in terms of how abnormal they appear when examined under a microscope in prostate cancer, as as defined by the AJCC Cancer Staging Manual, 6th Ed.","longName":"PRS_TUMOR_HISTO_G_ST","context":"CTEP","contextVersion":"2.31","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"3","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"GX","valueDescription":"Grade cannot be assessed","ValueMeaning":{"publicId":"2576932","version":"1","preferredName":"Grade cannot be assessed","longName":"2576932","preferredDefinition":"Grade cannot be assessed","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F991-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-09","endDate":null,"createdBy":"ALAIS","dateCreated":"2005-11-09","modifiedBy":"ALAIS","dateModified":"2005-11-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"03E16831-BCC9-6D9B-E044-0003BA3F9857","beginDate":"2002-02-11","endDate":null,"createdBy":"ALAIS","dateCreated":"2005-11-09","modifiedBy":"ALAIS","dateModified":"2005-11-09","deletedIndicator":"No"},{"value":"G1","valueDescription":"Well-differentiated (slight anaplasia) (Gleason 2-4)","ValueMeaning":{"publicId":"2576929","version":"1","preferredName":"Well-differentiated (slight anaplasia) (Gleason 2-4)","longName":"2576929","preferredDefinition":"Well-differentiated (slight anaplasia) (Gleason 2-4)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F98E-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-09","endDate":null,"createdBy":"ALAIS","dateCreated":"2005-11-09","modifiedBy":"ALAIS","dateModified":"2005-11-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"03E16831-BCCA-6D9B-E044-0003BA3F9857","beginDate":"2002-02-11","endDate":null,"createdBy":"ALAIS","dateCreated":"2005-11-09","modifiedBy":"ALAIS","dateModified":"2005-11-09","deletedIndicator":"No"},{"value":"G2","valueDescription":"Moderately differentiated (moderate anaplasia) (Gleason 5-6)","ValueMeaning":{"publicId":"2576930","version":"1","preferredName":"Moderately differentiated (moderate anaplasia) (Gleason 5-6)","longName":"2576930","preferredDefinition":"Moderately differentiated (moderate anaplasia) (Gleason 5-6)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F98F-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-09","endDate":null,"createdBy":"ALAIS","dateCreated":"2005-11-09","modifiedBy":"ALAIS","dateModified":"2005-11-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"03E16831-BCCB-6D9B-E044-0003BA3F9857","beginDate":"2002-02-11","endDate":null,"createdBy":"ALAIS","dateCreated":"2005-11-09","modifiedBy":"ALAIS","dateModified":"2005-11-09","deletedIndicator":"No"},{"value":"G3-4","valueDescription":"Poorly differentiated or undifferentiated (marked anaplasia) (Gleason 7-10)","ValueMeaning":{"publicId":"2576931","version":"1","preferredName":"Poorly differentiated or undifferentiated (marked anaplasia) (Gleason 7-10)","longName":"2576931","preferredDefinition":"Poorly differentiated or undifferentiated (marked anaplasia) (Gleason 7-10)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F990-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-09","endDate":null,"createdBy":"ALAIS","dateCreated":"2005-11-09","modifiedBy":"ALAIS","dateModified":"2005-11-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"03E16831-BCCC-6D9B-E044-0003BA3F9857","beginDate":"2002-02-11","endDate":null,"createdBy":"ALAIS","dateCreated":"2005-11-09","modifiedBy":"ALAIS","dateModified":"2005-11-09","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2427353","version":"1","preferredName":"Grade Stage","preferredDefinition":"Describes how closely a cancer resembles normal tissue of its same type, and the cancer's probable rate of growth:The extent of a cancer within the body, especially whether the disease has spread from the original site to other parts of the body.","longName":"C18000:C16899","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Histologic Grade","conceptCode":"C18000","definition":"The degree of abnormality of cancer cells, a measure of differentiation, the extent to which cancer cells are similar in appearance and function to healthy cells of the same tissue type. The degree of differentiation often relates to the clinical behavior of the particular tumor. Based on the microscopic findings, tumor grade is commonly described by one of four degrees of severity. Histopathologic grade of a tumor may be used to plan treatment and estimate the future course, outcome, and overall prognosis of disease. Certain types of cancers, such as soft tissue sarcoma, primary brain tumors, lymphomas, and breast have special grading systems.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Neoplasm Stage","conceptCode":"C16899","definition":"The extent of a cancer in the body.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"03E16831-BCB3-6D9B-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-09","endDate":null,"createdBy":"ALAIS","dateCreated":"2005-11-09","modifiedBy":"ONEDATA","dateModified":"2005-11-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"AJCC:American Joint Committee on Cancer Cancer Staging Manual, 6th Ed., 2002","workflowStatus":"RELEASED","registrationStatus":"Application","id":"03E16831-BCB4-6D9B-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-09","endDate":null,"createdBy":"ALAIS","dateCreated":"2005-11-09","modifiedBy":"SBR","dateModified":"2008-12-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008587","version":"2","longName":"Type of Disease","context":"CTEP","ClassificationSchemeItems":[{"publicId":"2811910","version":"1","longName":"Prostate","context":"CTEP"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Source","type":"DATA_ELEMENT_SOURCE","description":"AJCC Cancer Staging Manual, 6th Edition","url":null,"context":"CTEP"},{"name":"CRF Text","type":"Preferred Question Text","description":"Histopathologic Grade","url":null,"context":"CTEP"}],"origin":"AJCC:American Joint Committee on Cancer Cancer Staging Manual, 6th Ed., 2002","workflowStatus":"RELEASED","registrationStatus":"Application","id":"03E16831-BCD9-6D9B-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-09","endDate":null,"createdBy":"ALAIS","dateCreated":"2005-11-09","modifiedBy":"SBREXT","dateModified":"2006-09-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}